Drug Trial Radar · NCT00979537
Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 18, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Mar 2007
Primary completion
Mar 2007
Study completion Mar 2007
Sponsor
- Lead sponsor
- Mylan Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fed conditions.
Conditions
- Healthy
Interventions
Nisoldipine Extended-release Tablets, 40 mgDrug
Sular Tablets, 40 mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- BioequivalenceTime frame: within 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pracs Institute, Ltd
Fargo, North Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.